Coya Therapeutics, Inc. (COYA)
| Previous Close | 7.36 |
| Open | 7.49 |
| Bid | 7.09 x 100 |
| Ask | 7.57 x 100 |
| Day's Range | 7.21 - 7.55 |
| 52 Week Range | 3.21 - 10.69 |
| Volume | |
| Avg. Volume | 49,629 |
| Market Cap | 111.877M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.83 |
- Business Wire
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
HOUSTON, June 20, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the expansion of its research collaboration with the Houston Methodist Research Institute ("HMRI") through a sponsored research agreement (SRA) covering multiple initiatives.
Business WireCoya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
HOUSTON, June 11, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the publication of a peer-reviewed manuscript titled, "A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis," in the medical journal Frontiers in Neurolo
- Business Wire
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
HOUSTON, June 03, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, "A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis," in the medical journal Frontiers in Neurolog
